ClinicalTrials.gg
Active, not recruitingNCT06317441Updated Sep 30, 2026

The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms

An interventional study of Probiotic in Small Intestinal Bacterial Overgrowth and SIBO, sponsored by Nimble Science Ltd.. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Nimble Science Ltd. · Not applicable, Interventional, and Treatment

How we know

Updated Sep 30, 2026Now Active, not recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO). Two doses of probiotic will be evaluated against placebo.

Read the detailed description

The goal of this double-blinded, randomized, placebo-controlled clinical study is to evaluate whether two different doses of a probiotic formulation may have effect on gastrointestinal symptoms, as well as gut and small intestine microbiota, in participats suffering from SIBO. The two probiotic doses will be compared to a placebo.

The main research questions to be answered by this study are related to:

  • Probiotic effect on bloating and abdominal distension.
  • Probiotic effect on other gastrointestinal symptoms.
  • Probiotic effect on incidence of SIBO.
  • Probiotic effect on small intestine and gut microbiota.

The study will include a 2 month intervention with the investigational products and assessments will be conducted at baseline, mid-intervention, end-of-intervention, and follow-up period, with the exception of SIBO diagnosis, which will be conducted at baseline and at follow-up.

02

Conditions studied

  • Small Intestinal Bacterial Overgrowth
  • SIBO

Keywords

  • Functional abdominal bloating and distension
  • Functional Diarrhea
  • Irritable Bowel Syndrome with Diarrhea
  • Irritable Bowel Syndrome
  • Abdominal Bloating
  • IBS
  • IBS-D
  • FABD
  • Functional Gastrointestinal Disorders
  • FGID
03

In context

Dilatation, Pathologic

121 studies on the registry are indexed under Dilatation, Pathologic; 19 are open to participants now.

This study's planned enrollment of 105 is above the median of 82 across 84 interventional studies indexed under Dilatation, Pathologic.

Browse Dilatation, Pathologic studies →

Lead sponsor

Nimble Science Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-65 years old at the inclusion of the study, both female and male subjects.
  2. Signed ; willing and able to comply with study procedures.
  3. Willing to maintain their diet and physical activity levels during the study.
  4. Able to swallow a size-00 capsule (23mm length and 9mm width).
  5. Participants with at least one of the following Rome IV diagnoses: FABD, functional diarrhea, IBS-M, or IBS-D.
  6. Baseline weekly average of worst daily (in past 24 hours) abdominal bloating/distension score of >= 3.0 on a 0-to-10-point scale.
  7. Participants with abnormal LHBT following the North American Consensus recommendations (A rise in hydrogen of ≥20 ppm by 90 min).

Exclusion criteria

Exclusion Criteria:

  1. History of less than three (3) bowel movements per week.
  2. With the diagnosis of IBS-C.
  3. Prior gastrointestinal disease, surgery, or abdominal or pelvic radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, any IBD, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable.
  4. Persons with central venous catheters.
  5. History of known structural gastrointestinal abnormalities such as structures or fistulas leading to mechanical obstruction.
  6. Known history abdominal radiation treatment.
  7. Use of any medications in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, or GLP-1 analogues); laxative use is allowed if used less than 3 times a week and it is willing to keep unchanged in the week prior to the SIMBA capsule ingestions. Proton pump inhibitors (PPIs) are allowed provided a of 48 hours is respected before swallowing the SIMBA capsules and PPI treatment is resumed only 4 hours thereafter.

    o Prokinetic use. Potential participants who are not using prokinetics to treat SIBO may be eligible after a 2-week washout period, and willing to not use prokinetics for the study duration.

  8. Unable to stop using laxatives or prokinetic medications for 4 days before the study procedure (BT). Laxatives can be resumed after the test is conducted.
  9. Organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, Ogilvie's syndrome.
  10. Celiac disease (treated or untreated).
  11. Any significant heart, liver, lung, kidney, blood, endocrine or nervous system disease, which in the opinion of the investigator, would adversely affect study safety or outcome.
  12. Cancer diagnosis or treatment within the past year (non-melanoma skin cancers are acceptable).
  13. Gastrointestinal inflammatory diseases, including ulcerative colitis, Crohn's disease, microscopic colitis.
  14. Participants with IBS presenting with alarm symptoms such as: rectal bleeding, unexplained weight loss, iron deficiency anemia, and nocturnal symptoms,
  15. Participants over the age of 50 or older who have not had:

    • a colon cancer screening by either a negative FIT or FOBT test within the last 2 years; OR
    • a colonoscopy in the prior 10 years which was negative for colorectal cancer
  16. Epilepsy diagnosis.
  17. History or diagnosis of immunological diseases, infectious diseases or immune-compromised conditions, which in the opinion of the investigator, would adversely affect study safety or outcome. Such as, but not limited to, hepatitis, tuberculosis, positive, Parkinson's, multiple sclerosis, AIDS, lymphoma, and long-term treatment.
  18. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration.
  19. Antibiotic use (except for topical use) ≤ 12 weeks prior to screening. Potential participants may be eligible once a 12-week washout is completed.
  20. Regular use of probiotics, prebiotics or synbiotics (including food and drinks containing added probiotics and/or probiotic yogurts with live, active cultures) within 1 month prior to screening. Potential participants may be eligible once a 1-month washout is completed.
  21. Any prior Fecal Microbiota Transplantation.
  22. Pregnant or breastfeeding.
  23. Planning to become pregnant.
  24. Alcohol or drug abuse.
  25. Allergy to the components present in the probiotic and placebo capsules.
  26. Are non-English speaking.
  27. Are scheduled for an MRI at any time during the study. Potential participants may be eligible to participate once their MRI procedure is completed.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Probiotic (High dose)

    A high dosage probiotic per capsule

    Dietary Supplement: Probiotic

  • Experimental
    Probiotic (Low dose)

    A low dosage probiotic per capsule

    Dietary Supplement: Probiotic

  • No intervention
    Control group (Placebo)

    No probiotic dosage

Interventions

  • Dietary supplementProbiotic

    The intervention consists of a probiotic either with a low or high dosage

06

What researchers measure

Primary outcomes

  1. Change in bloating/distension severity

    The primary outcome will assess the changes in weekly median severity of bloating/distension, defined as pressure, fullness or sensation of increased girth with a daily assessment with an ordinal scale between probiotic groups and placebo.

    Time frame: From baseline to end of intervention (week 8).

Secondary outcomes

  1. Median bloating-free days

    Median bloating-free days per week at each intervention week and follow up

    Time frame: Each intervention week and follow up (week 12) compared to baseline.

  2. Change in median bloating/distension severity

    Change in median bloating/distension severity assessed by an ordinal scale (0 no severity- 10 extreme severity) at all intervention weeks (with the exception of end-of-intervention, as described in the primary outcome)

    Time frame: At all intervention weeks (with the exception of end-of-intervention, as described in the primary outcome) and follow-up (week 12) compared to baseline.

  3. Change in abdominal discomfort/pain

    Change in abdominal discomfort/pain assessed by an ordinal scale (0 no pain - 10 extreme pain)

    Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline

  4. Changes in gastrointestinal symptoms

    Changes in gastrointestinal symptoms assessed with GSRS

    Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.

  5. Changes in stool frequency and consistency

    Changes in stool frequency and consistency assessed with the Bristol Stool Scale (scoring 1 watery - 7 hard)

    Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.

  6. Changes in the quality of life

    Changes in the quality of life assessed with the Short Form (SF)-36 questionnaire

    Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.

  7. Changes in reflux incidence and severity

    Changes in reflux incidence and severity assessed with the modified reflux symptoms (mRESQ)

    Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.

  8. Changes in the severity of IBS symptoms

    Changes in the severity of IBS symptoms assessed with IBS Severity Scoring System (IBS-SSS) questionnaire

    Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.

  9. Recovery rate of the probiotic strain

    Recovery rate of the probiotic strain in small intestine and stool specimens

    Time frame: At mid-intervention (week 4) end of intervention (week 8), and follow-up (week 12) compared to baseline.

  10. Microbiome changes within small intestine, fecal and saliva samples

    Changes in the the bacterial populations with the small intestine, fecal and saliva microbiomes represented as a diversity ratio

    Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.

  11. Investigation how the microbiome and SIBO associate with each other though bacterial population analyses.

    Exploring the correlation of select bacterial populations with SIBO through analysis of the small intestine and fecal microbiomes using metagenomics methodologies.

    Time frame: Through study completion, an average of 1 year

  12. Change in SIBO positivity rate

    Change in SIBO positivity rate assessed by glucose breath test

    Time frame: Through study completion, an average of 1 year

Other outcomes

  1. Exploratory metabolomic analysis

    To investigate whether certain metabolites present in the small intestine, fecal, saliva samples may be associated with the presence/absence of SIBO. Using untargeted metabolomic methodologies.

    Time frame: Through study completion, an average of 1 year

  2. Exploratory: Quantifying the probiotic cell proportions

    Determine the proportion of probiotic cells in spore versus germinated form using qPCR methodologies

    Time frame: Through study completion, an average of 1 year

  3. Safety outcomes

    To collect safety data on the probiotic formulation and the SIMBA capsule by monitoring adverse events throughout the study.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Select data with be shared with the participants

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2027, 33 months after the start.

Of 27 interventional studies with no phase under Dilatation, Pathologic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 33 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2026 → Apr 2027 and completion Dec 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 19, 2024
StartActual
Jul 10, 2024
Primary completionEst.
Apr 2027was Dec 2026
CompletionEst.
Sep 2027was Dec 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 30, 2026
Start date
Jul 20, 2024→Jul 10, 2024
Sep 30, 2026
Primary completion
Dec 2026→Apr 2027
Sep 30, 2026
Study completion
Dec 2026→Sep 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Active, not recruiting
    Start date Jul 20, 2024→Jul 10, 2024
    Primary completion Dec 2026→Apr 2027
    Study completion Dec 2026→Sep 2027
    + 5 other changes: verification date, oversight details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06317441
Lead sponsor
Nimble Science Ltd.
Collaborators
Lallemand Health Solutions
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Jul 10, 2024
Primary completion
Apr 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion